ADHD extended-release tablets approved by FDA
FDA approval has been granted to new generic ADHD extended-release tablets from Mallinckrodt.
Pharmaceuticals business Mallinckrodt has received approval from the US Food and Drug Administration for the manufacturing and marketing of a generic version of Concerta tablets for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
The methylphenidate HCI extended-release tablets will be produced in 27, 36 and 54mg dosage strengths, with the 27mg tablets to be launched immediately.
Such tablets are used for the treatment of ADHD in children aged six years and above, as well as adolescents and adults with the condition up to the age of 65.
Mallinckrodt said that it holds separate 180-day exclusivity periods for each of the dosage strengths starting from their respective commercial launches. With that in mind, it intends to have the 36mg and 54mg tablets available commercially by the end of the first calendar quarter of 2013.
It is also currently applying for approval of an 18mg dosage strength methylphenidate HCI extended-release tablet.
Mark Trudeau, president of the company, said: "This approval represents an important addition to our line of generic pharmaceutical products and we look forward to providing an affordable treatment option to patients coping with ADHD.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance